XML 37 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Corrections to Previously Issued Consolidated Financial Statements (Details Textual) - USD ($)
 2 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2015
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Sep. 30, 2016
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Collaborative agreement, description       Company discovered that there was a delay of accrual for the two payments in total of $10,000,000 as set forth in the Collaborative Agreement: 1) 3.5% of total payment related to the upfront payment shall be made upon the execution of the Collaborative Agreement; and 2) 6.5% of the total payment shall be made upon the first IND submission (which was submitted in March 2016).    
Due to related party   $ 950,000   $ 950,000   $ 6,500,000
Total Liabilities   1,029,160   1,029,160   6,556,470
Additional paid-in capital   10,583,912   10,583,912   4,733,461
Accumulated deficit   (11,720,409)   (11,720,409)   (11,323,401)
Total equity (deficit)   (922,750)   (922,750)   (6,379,118)
Selling, general and administrative expenses   208,315 $ 108,732 393,503 $ 110,359  
Research and development expenses   25,150 6,500,000 50,348 10,000,000  
Net loss from operations   (236,841) (6,608,764) (377,227) (10,110,391)  
Loss from continuing operations before income taxes   (255,841) (6,608,712) (396,178) (10,110,147)  
Net loss from continuing operations   $ (256,671) $ (6,608,712) $ (397,008) $ (10,110,147)  
Basic and diluted loss per share   $ 0.00 $ (0.03) $ 0.00 $ (0.05)  
Net loss from continuing operations   $ (256,671) $ (6,608,712) $ (397,008) $ (10,110,147)  
Issuance of common stocks for compensation       (3,376)  
(Decrease) increase in due to related party       (650,000) 9,977,483  
Net cash used in operating activities       $ (1,017,127) (428,849)  
Previously Reported on Form 10K [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party      
Total Liabilities           56,470
Additional paid-in capital           4,733,401
Accumulated deficit     (425,749)   (425,749) (4,823,401)
Total equity (deficit)           120,882
Selling, general and administrative expenses           4,497,263
Research and development expenses      
Net loss from operations           (4,497,295)
Loss from continuing operations before income taxes           (4,506,963)
Net loss from continuing operations     $ (108,712)   $ (110,147) $ (4,507,799)
Basic and diluted loss per share     $ 0.00   $ 0.00 $ 0.00
Net loss from continuing operations     $ (108,712)   $ (110,147) $ (4,507,799)
Issuance of common stocks for compensation           1,295,324
(Decrease) increase in due to related party           (22,517)
Net cash used in operating activities $ (517)          
Adjustments No.1 [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party     10,000,000   10,000,000 6,500,000
Total Liabilities           6,500,000
Additional paid-in capital          
Accumulated deficit     (10,000,000)   (10,000,000) (6,500,000)
Total equity (deficit)           (6,500,000)
Selling, general and administrative expenses           (3,500,060)
Research and development expenses     6,500,000   10,000,000 10,000,000
Net loss from operations           (6,499,940)
Loss from continuing operations before income taxes           (6,499,940)
Net loss from continuing operations     $ (6,500,000)   $ (10,000,000) $ (6,499,940)
Basic and diluted loss per share     $ (0.03)   $ (0.05) $ (0.06)
Net loss from continuing operations     $ (6,500,000)   $ (10,000,000) $ (6,499,940)
Issuance of common stocks for compensation           (60)
(Decrease) increase in due to related party           6,500,000
Net cash used in operating activities          
Adjustments No.2 [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party          
Total Liabilities          
Additional paid-in capital           60
Accumulated deficit          
Total equity (deficit)          
Selling, general and administrative expenses           60
Research and development expenses          
Net loss from operations           (60)
Loss from continuing operations before income taxes           (60)
Net loss from continuing operations           $ (60)
Basic and diluted loss per share           $ 0.00
Net loss from continuing operations           $ (60)
Issuance of common stocks for compensation           60
(Decrease) increase in due to related party          
Net cash used in operating activities (198)          
Restated [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party     10,000,000   10,000,000 6,500,000
Total Liabilities           6,556,470
Additional paid-in capital           4,733,461
Accumulated deficit     (10,425,749)   (10,425,749) (11,323,401)
Total equity (deficit)           (6,379,118)
Selling, general and administrative expenses           997,263
Research and development expenses     6,500,000   10,000,000 10,000,000
Net loss from operations           (10,997,295)
Loss from continuing operations before income taxes           (11,006,963)
Net loss from continuing operations     $ (6,608,712)   $ (10,110,147) $ (11,007,799)
Basic and diluted loss per share     $ (0.03)   $ (0.05) $ (0.06)
Net loss from continuing operations     $ (6,608,712)   $ (10,110,147) $ (11,007,799)
Issuance of common stocks for compensation           1,295,324
(Decrease) increase in due to related party           $ 6,477,483
Net cash used in operating activities $ (715)